Axonally derived matrilin-2 induces proinflammatory responses that exacerbate autoimmune neuroinflammation

Journal of Clinical Investigation

Volumn 124, Issue 11, 2014, Pages 5042-5056

  Jonas, Anna ^a   Thiem, Stefan ^b   Kuhlmann, Tanja ^c   Wagener, Raimund ^d   Aszodi, Attila ^e   Nowell, Cameron ^b   Hagemeier, Karin ^c   Laverick, Louise ^f   Perreau, Victoria ^a,f   Jokubaitis, Vilija ^a,f   Emery, Ben ^a,f   Kilpatrick, Trevor ^a,f   Butzkueven, Helmut ^a,f   Gresle, Melissa ^f  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MATRILIN; MATRILIN 2; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; AUTACOID; MATN2 PROTEIN, MOUSE; TLR4 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AXONAL INJURY; CELL ACTIVATION; COCULTURE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXTRACELLULAR MATRIX; FEMALE; GENE DELETION; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; MACROPHAGE CULTURE; MALE; MOUSE; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NONHUMAN; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TISSUE SECTION; WHITE MATTER; WILD TYPE; ANIMAL; C57BL MOUSE; CELL CULTURE; IMMUNOLOGY; KNOCKOUT MOUSE; MACROPHAGE; METABOLISM; MOTOR CORTEX; NERVE FIBER; PHYSIOLOGY; SPINAL CORD INJURY; TRANSCRIPTION INITIATION;

ANIMALS; AXONS; CELLS, CULTURED; COCULTURE TECHNIQUES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; MACROPHAGES; MALE; MATRILIN PROTEINS; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR CORTEX; SIGNAL TRANSDUCTION; SPINAL CORD INJURIES; TOLL-LIKE RECEPTOR 4; TRANSCRIPTIONAL ACTIVATION;

EID: 84908610662     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI71385     Document Type: Article

References (46)

1. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338(5):278-285.
2. Kornek B, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: A comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol. 2000;157(1):267-276.
3. Lovas G, Szilagyi N, Majtenyi K, Palkovits M, Komoly S. Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain. 2000;123(pt 2):308-317.
4. Lucchinetti CF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med. 2011;365(23):2188-2197.
5. Dutta R, et al. Activation of the ciliary neurotrophic factor (CNTF) signaling pathway in cortical neurons of multiple sclerosis patients. Brain. 2007;130(pt 10):2566-2576.
6. Gresle MM, et al. Validation of a novel biomarker for acute axonal injury in experimental autoimmune encephalomyelitis. J Neurosci Res. 2008;86(16):3548-3555.
7. Butzkueven H, Emery B, Cipriani T, Marriott MP, Kilpatrick TJ. Endogenous leukemia inhibitory factor production limits autoimmune demyelination and oligodendrocyte loss. Glia. 2006;53(7):696-703.
8. Palace J. Neuroprotection and repair. J Neurol Sci. 2008;265(1-2):21-25.
9. Schaefer L, et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest. 2005;115(8):2223-2233.
10. Merline R, et al. Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and microRNA-21. Sci Signal. 2011;15(199):ra75.
11. Kim S, et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature. 2009;457(7225):102-106.
12. Termeer C, et al. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med. 2002;195(1):99-111.
13. Moreth K, et al. The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis. J Clin Invest. 2010;120(12):4251-4272.
14. Schaefer L, Iozzo RV. Small leucine-rich proteoglycans, at the crossroad of cancer growth and inflammation. Curr Opin Genet Dev. 2012;22(1):56-57.
15. Schaefer L. Small leucine-rich proteoglycans in kidney disease. J Am Soc Nephrol. 2011;22(7):1200-1207.
16. Schaefer L. Extracellular matrix molecules: endogenous danger signals as new drug targets in kidney diseases. Curr Opin Pharmacol. 2010;10(2):185-190.
17. Klatt AR, Becker AK, Neacsu CD, Paulsson M, Wagener R. The matrilins: modulators of extracellular matrix assembly. Int J Biochem Cell Biol. 2011;43(3):320-330.
18. Piecha D, et al. Matrilin-2, a large, oligomeric matrix protein, is expressed by a great variety of cells and forms fibrillar networks. J Biol Chem. 1999;274(19):13353-13361.
19. Segat D, et al. Expression of matrilin-1, -2 and -3 in developing mouse limbs and heart. Matrix Biol. 2000;19(7):649-655.
20. Piecha D, et al. Expression of matrilin-2 in human skin. J Invest Dermatol. 2002;119(1):38-43.
21. Szabo E, et al. Expression of matrilin-2 in liver cirrhosis and hepatocellular carcinoma. Pathol Oncol Res. 2008;14(1):15-22.
22. Malin D, et al. The extracellular-matrix protein matrilin-2 participates in peripheral nerve regeneration. J Cell Sci. 2009;122(pt 7):995-1004.
23. Comabella M, Martin R. Genomics in multiple sclerosis-current state and future directions. J Neuroimmunol. 2007;187(1-2):1-8.
24. Linker RA, Lee DH. Models of autoimmune demyelination in the central nervous system: on the way to translational medicine. Exp Transl Stroke Med. 2009;1:5.
25. Mates LI, Nicolae C, Morgelin M, Deak F, Kiss I, Aszodi A. Mice lacking the extracellular matrix adaptor protein matrilin-2 develop without obvious abnormalities. Matrix Biol. 2004;23(3):195-204.
26. Muratoglu S, et al. Primary structure of human matrilin-2, chromosome location of the MATN2 gene and conservation of an AT-AC intron in matrilin genes. Cytogenet Cell Genet. 2000;90(3):323-327.
27. Deak F, Piecha D, Bachrati C, Paulsson M, Kiss I. Primary structure and expression of matrilin-2, the closest relative of cartilage matrix protein within the von Willebrand factor type A-like module superfamily. J Biol Chem. 1997;272(14):9268-9274.
28. Strand AD, et al. Conservation of regional gene expression in mouse and human brain. PLoS Genet. 2007;3(4):e59.
29. Baeten KM, Akassoglou K. Extracellular matrix and matrix receptors in blood-brainbarrier formation and stroke. Dev Neurobiol. 2011;71(11):1018-1039.
30. Babelova A, et al. Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J Biol Chem. 2009;284(36):24035-24048.
31. Magalhaes PO, et al. Methods of endotoxin removal from biological preparations: A review. J Pharm Pharm Sci. 2007;10(3):288-404.
32. Popovic ZV, et al. The proteoglycan biglycan enhances antigen-specific T cell activation potentially via MyD88 and TRIF pathways and triggers autoimmune perimyocarditis. J Immunol. 2011;187(12):6217-6226.
33. Chen GY, Nunez G. Sterile inflammation: Sensing and reacting to damage. Nat Rev Immunol. 2010;10(12):826-837.
34. Dinarello CA. A clinical perspective of IL-1β as the gatekeeper of inflammation. Eur J Immunol. 2011;41(5):1203-1217.
35. Akira S, Takeda K. Toll-like receptor signaling. Nat Rev Immunol. 2004;4(7):499-511.
36. Derbali H, et al. Increased biglycan in aortic valve stenosis leads to the overexpression of phospholipid transfer protein via Toll-like receptor 2. Am J Pathol. 2010;176(6):2638-2645.
37. Moreth K, Iozzo RV, Schaefer L. Small leucine- rich proteoglycans orchestrate receptor crosstalk during inflammation. Cell Cycle. 2012;11(11):2084-2091.
38. Tang SC, et al. Pivotal role for neuronal Tolllike receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci U S A. 2007;104(34):13798-13803.
39. Mattson MP, Maudsley S, Martin B. A neural signaling triumvirate that influences ageing and age-related disease: insulin/IGF-1, BDNF and serotonin. Ageing Res Rev. 2004;3(4):445-464.
40. Mattson MP, Barger SW, Begley JG, Mark RJ. Calcium, free radicals and ecitotoxic neuronal death in primary cell culture. Methods Cell Biol. 1995;46:187-216.
41. Adachi O, et al. Targeted disruption of the MyD88 gene results in loss of IL-1- And IL-18-mediated function. Immunity. 1998;9(1):143-150.
42. Gresle MM, et al. Leukemia inhibitory factor protects axons in experimental autoimmune encephalomyelitis via an oligodendrocyte- independent mechanism. PLoS One. 2012;7(10):e47379.
43. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-408.
44. Munro KM, et al. EphA4 receptor tyrosine kinase is a modulator of onset and disease severity of experimental autoimmune encephalomyelitis (EAE). PLoS One. 2013;8(2):e55948.
45. Lassmann H. Review: The architecture of inflammatory demyelinating lesions: implications for studies on pathogenesis. Neuropathol Appl Neurobiol. 2011;37(7):698-710.
46. Fleetwood AJ, Lawrence T, Hamilton JA, Cook AD. Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation. J Immunol. 2007;178(8):5245-5252.